Results from 327 women demonstrated: Significant increases in satisfying sexual events compared to placebo at 1.25 mg and 1.75 mg doses Improved Female Sexual Function Index total scores (mean improvement of 3.6 points vs 1.9 for placebo) Reduced sexual distress as measured by Female Sexual Distress Scale scores Dose-dependent response with optimal effects at 1.75 mg Two Phase 3 trials (RECONNECT studies) enrolled over 1,200 premenopausal women with acquired, generalized HSDD and confirmed efficacy at the 1.75 mg dose administered subcutaneously at least 45 minutes before anticipated sexual activity
Discussions of the exact egg development and hatching cycle of the Gila monster came to an abrupt and unexpected end on October 28, 2016, when a backhoe was digging at the outer walls of a house in a suburb of northern Tucson
Now, with patent protections expiring today, it is being said that a new era of affordable and widely available weight loss medication may be on the horizon
This question comes up regularly
Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps-a scoping review
Glutathione is an essential antioxidant that interacts with many different processes